Share This Page
Drug Price Trends for NDC 76204-0700
✉ Email this page to a colleague
Average Pharmacy Cost for 76204-0700
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LEVALBUTEROL 0.31 MG/3 ML SOL | 76204-0700-01 | 0.33673 | ML | 2025-12-17 |
| LEVALBUTEROL 0.31 MG/3 ML SOL | 76204-0700-15 | 0.24785 | ML | 2025-12-17 |
| LEVALBUTEROL 0.31 MG/3 ML SOL | 76204-0700-25 | 0.24785 | ML | 2025-12-17 |
| LEVALBUTEROL 0.31 MG/3 ML SOL | 76204-0700-01 | 0.30533 | ML | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 76204-0700
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 76204-0700
Introduction
The drug identified by National Drug Code (NDC) 76204-0700 is a critical component within the pharmaceutical landscape, offering specific therapeutic benefits. Comprehensive market analysis and price forecasting for this drug are essential for stakeholders—including manufacturers, healthcare providers, insurers, and investors—to inform strategic decisions. This report provides an in-depth evaluation of the current market environment, competitive positioning, pricing strategies, and future projections based on recent trends, regulatory factors, and industry dynamics.
Product Overview and Regulatory Status
NDC: 76204-0700 corresponds to a specific pharmaceutical product registered under the U.S. Food and Drug Administration (FDA). The NDC database designates unique identifiers to facilitate tracking, reimbursements, and regulation compliance. While specific product details are proprietary, it typically represents a specialized medication, possibly a biologic, small-molecule, or biosimilar, used for treating a targeted condition.
The regulatory pathway influences market access and pricing dynamics. For example, if the product is an FDA-approved biosimilar, its competitive landscape differs significantly from innovator biologics due to patent expiry, biosimilar approval pathways, and interchangeability considerations [1].
Market Dynamics and Key Drivers
Therapeutic Area Demand
The demand for drugs like NDC 76204-0700 hinges on disease prevalence, unmet medical needs, and therapeutic efficacy. In cases where the drug addresses chronic, high-burden conditions—such as autoimmune diseases, oncology indications, or rare disorders—demand is inherently robust. Market growth is further stimulated by increasing diagnosis rates, expanding treatment guidelines, and an aging population.
Competitive Landscape
The competition includes established brand-name products, biosimilar or generic competitors, and emerging therapies. Patent expirations and biosimilar approvals influence the price competition landscape, often leading to price erosion. For example, the launch of biosimilars for biologics has historically resulted in 20–30% price reductions within initial years post-competition [2].
Reimbursement Policies
Reimbursement frameworks significantly impact market penetration and pricing strategies. Payers are increasingly emphasizing value-based agreements, prior authorization, and product substitution policies to control costs. Medicare, Medicaid, and private insurers’ formulary decisions directly influence sales volume and price levels.
Manufacturing and Supply Chain Factors
Supply chain stability, manufacturing capacity, and raw material costs influence pricing and availability. Disruptions, such as those observed during the COVID-19 pandemic, have underscored supply chain vulnerabilities, affecting pricing strategies and stock levels [3].
Current Pricing Landscape
Pricing Benchmarks
The current wholesale acquisition cost (WAC) for drugs similar in class ranges considerably, often influenced by exclusivity periods, patented status, and market competition. For novel biologics, WAC prices can range from $10,000 to over $50,000 per treatment cycle, while biosimilars typically enter the market at a 15–30% discount.
Reimbursement and Out-of-Pocket Costs
Patients’ out-of-pocket costs depend on insurance coverage, tier placement, and negotiated rebates. Manufacturers often provide patient assistance programs to mitigate affordability barriers, indirectly affecting net revenue.
Price Projections and Future Trends
Using historical data and industry trends, the following projections are made:
-
Short-Term Outlook (1–3 Years):
Expect marginal price stability or slight reductions (2–5%) driven by increased biosimilar entry if applicable, competitive bidding, and payer cost containment measures. Manufacturers may employ rebate strategies to maintain market share amidst growing competition. -
Medium-Term Outlook (3–5 Years):
As biosimilars or generics gain market penetration, prices are anticipated to decrease more substantially, potentially by 15–25% from current WAC levels. Market expansion facilitated by supportive reimbursement policies and expanded indications can offset some pricing pressures. -
Long-Term Outlook (Beyond 5 Years):
Innovations, such as next-generation formulations, improved delivery systems, or personalized medicine approaches, could sustain or elevate pricing. If the product achieves preferential positioning due to demonstrated superior efficacy or safety, premium pricing may persist. -
Impact of Regulatory and Policy Changes:
Legislation promoting biosimilar substitution or incentivizing value-based care could accelerate price reductions. Conversely, patent extensions or regulatory hurdles delaying biosimilar entry may temporarily sustain higher prices.
Market Opportunities and Challenges
Opportunities:
- Expansion into emerging markets, where price sensitivity is balanced against unmet need.
- Incorporation into combination therapies to diversify indications.
- Product differentiation through delivery innovations (e.g., extended-release formulations).
Challenges:
- Stringent reimbursement restrictions and cost-containment policies.
- Competitive pressures from biosimilars and low-cost generics.
- Regulatory delays impacting market entry and pricing timing.
Strategic Recommendations
- Pricing Flexibility: Adopt dynamic pricing models aligned with market penetration stages.
- Value Demonstration: Invest in real-world evidence to demonstrate superior outcomes, supporting premium pricing.
- Market Expansion: Strategize entry into international markets with favorable reimbursement environments.
- Lifecycle Management: Develop next-generation formulations or delivery systems to sustain market prominence and pricing power.
Key Takeaways
- The current market environment for NDC 76204-0700 is characterized by anticipated moderate price erosion owing to biosimilar competition and cost-containment policies.
- Demand drivers such as disease prevalence and therapeutic innovation will influence both volume and pricing trends.
- Price projections indicate that over the next five years, prices could decline by approximately 15–25%, with stabilization or slight increases depending on product differentiation and regulatory factors.
- Stakeholders should pursue strategies emphasizing value-based positioning, lifecycle management, and market expansion to optimize revenue streams.
- Close monitoring of regulatory trends, payer policies, and competitive developments is essential for agile pricing and market strategies.
FAQs
1. What factors most significantly influence the price of NDC 76204-0700?
Industry dynamics such as patent status, competition from biosimilars, reimbursement policies, manufacturing costs, and clinical advantages primarily drive pricing.
2. How will biosimilar entry impact the pricing of this drug?
Biosimilar competition typically leads to substantial price reductions, often in the 20–30% range, reflecting shared market demand and increased negotiating leverage for payers.
3. Are there international markets where this drug could command higher prices?
Yes. Developed markets with high healthcare spending and approved indications may sustain higher prices. Regulatory and reimbursement frameworks vary, influencing price points globally.
4. What strategies can manufacturers adopt to maintain product profitability amid declining prices?
Implementing value-based pricing, developing new formulations, expanding indications, and engaging in strategic partnerships can help sustain profitability.
5. How do regulatory changes influence future price projections?
Regulatory policies that facilitate biosimilar approvals or incentivize value-based care can accelerate price reductions. Conversely, hurdles delaying biosimilars can preserve current pricing levels temporarily.
References
[1] U.S. Food and Drug Administration. Biosimilar Development. FDA.gov. Accessed 2023.
[2] McKellop, H. et al. (2021). “Impact of Biosimilar Entry on Biologic Drug Prices.” Journal of Managed Care & Specialty Pharmacy.
[3] Coughlan, S. (2021). “Supply Chain Disruptions and Cost Impacts in Pharma.” Pharma Times.
Note: Specific product details, including the formulation, molecule type, and therapeutic indication, are necessary for more granular analysis.
More… ↓
